Below are the most recent publications written about "DNA Topoisomerases, Type II" by people in Profiles.
-
Burbulla LF, Schelling C, Kato H, Rapaport D, Woitalla D, Schiesling C, Schulte C, Sharma M, Illig T, Bauer P, Jung S, Nordheim A, Sch?ls L, Riess O, Kr?ger R. Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet. 2010 Nov 15; 19(22):4437-52.
-
Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z. Adenoid cystic carcinomas of the breast have low Topo IIa expression but frequently overexpress EGFR protein without EGFR gene amplification. Hum Pathol. 2010 Nov; 41(11):1617-23.
-
Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol. 2009 Aug 20; 27(24):3881-6.
-
Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6.
-
Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA, Rebbaa A. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol. 2009 Jan; 296(1):C65-74.
-
Hansel DE, Ashfaq R, Rahman A, Wanzer D, Yeo CJ, Wilentz RE, Maitra A. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment. Am J Clin Pathol. 2005 Jan; 123(1):28-35.
-
Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother. 2002 Jan; 46(1):119-24.
-
Mirski SE, Voskoglou-Nomikos T, Young LC, Deeley RG, Campling BG, Gerlach JH, Cole SP. Simultaneous quantitation of topoisomerase II alpha and beta isoform mRNAs in lung tumor cells and normal and malignant lung tissue. Lab Invest. 2000 Jun; 80(6):787-95.
-
Mirski SE, Sparks KE, Yu Q, Lang AJ, Jain N, Campling BG, Cole SP. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. Int J Cancer. 2000 Feb 15; 85(4):534-9.
-
Jain N, Lam YM, Pym J, Campling BG. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer. 1996 May 1; 77(9):1797-808.